Literature DB >> 16399448

Making unresectable hepatic colorectal metastases resectable--does it work?

Jean-Nicolas Vauthey1, Daria Zorzi, Timothy M Pawlik.   

Abstract

In patients with colorectal liver metastases, surgical resection is the treatment of choice. Reported 5-year survival rates with surgical resection range from 40% to 58%. The definition of resectability has changed over the past decade from a limited number of metastases (three to four) to any number of metastases as long as resection can be completed with anticipated negative surgical margins. In patients with bilobar hepatic colorectal metastases, potentially curative resection after preoperative chemotherapy may be possible only with an extended hepatectomy (bilobar hepatic resection of five or more hepatic segments). Extended hepatic resection should be considered because it is associated with a near-zero mortality rate with modern surgical techniques. If the estimated volume of liver that remains after resection is too small to permit safe extended hepatectomy (ie, 20% or less of the total estimated liver volume), preoperative portal vein embolization can be safely used to increase the volume of the future liver remnant and improve postoperative liver function. Other approaches for patients with bilobar metastases include two-stage hepatic resection and the combined use of resection with radiofrequency ablation.

Entities:  

Mesh:

Year:  2005        PMID: 16399448     DOI: 10.1053/j.seminoncol.2005.04.030

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  10 in total

1.  External validation of a pre-operative nomogram predicting peri-operative mortality risk after liver resections for malignancy.

Authors:  Mashaal Dhir; Srinevas K Reddy; Lynette M Smith; Fred Ullrich; James Wallis Marsh; Allan Tsung; David A Geller; Chandrakanth Are
Journal:  HPB (Oxford)       Date:  2011-09-16       Impact factor: 3.647

2.  Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT.

Authors:  L Bacigalupo; S Aufort; M C Eberlé; E Assenat; M Ychou; B Gallix
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

3.  Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention.

Authors:  A A J M Van Tilborg; M R Meijerink; C Sietses; J H T M Van Waesberghe; M O Mackintosh; S Meijer; C Van Kuijk; P Van Den Tol
Journal:  Br J Radiol       Date:  2010-12-15       Impact factor: 3.039

4.  Recent trends in liver resection surgery activity and population utilization rates in English regions.

Authors:  Georgios Lyratzopoulos; Claire Tyrrell; Paul Smith; Julia Yelloly
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

Review 5.  Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer.

Authors:  Jianmin Xu; Xinyu Qin; Jianping Wang; Suzhan Zhang; Yunshi Zhong; Li Ren; Ye Wei; Shaochong Zeng; Deseng Wan; Shu Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-28       Impact factor: 4.553

6.  Pre-operative nomogram to predict risk of peri-operative mortality following liver resections for malignancy.

Authors:  Mashaal Dhir; Lynette M Smith; Fred Ullrich; Premila D Leiphrakpam; Quan P Ly; Aaron R Sasson; Chandrakanth Are
Journal:  J Gastrointest Surg       Date:  2010-09-08       Impact factor: 3.452

Review 7.  Designing liver resections and pushing the envelope with resections for hepatic colorectal metastases.

Authors:  Mary L Guye; Hans F Schoellhammer; Louisa W Chiu; Joseph Kim; Lily L Lai; Gagandeep Singh
Journal:  Indian J Surg Oncol       Date:  2013-07-12

8.  Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases.

Authors:  Reza Kianmanesh; Stefano Scaringi; Jean-Marc Sabate; Benjamin Castel; Nathalie Pons-Kerjean; Benoit Coffin; Jean-Marie Hay; Yves Flamant; Simon Msika
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

Review 9.  Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis.

Authors:  Stuart M Robinson; Colin H Wilson; Alastair D Burt; Derek M Manas; Steven A White
Journal:  Ann Surg Oncol       Date:  2012-07-06       Impact factor: 5.344

10.  Interleukin-6 is required for cell cycle arrest and activation of DNA repair enzymes after partial hepatectomy in mice.

Authors:  Shingo Tachibana; Xiuying Zhang; Kazushige Ito; Yoshihiro Ota; Andrew M Cameron; George Melville Williams; Zhaoli Sun
Journal:  Cell Biosci       Date:  2014-02-03       Impact factor: 7.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.